Login to Your Account

Vernal Aquinox: Series C Gets $18M to Finish Phase II Trials

By Randy Osborne
Staff Writer

Wednesday, April 3, 2013
The new round of Phase II studies funded by Aquinox Pharmaceuticals Inc.'s $18 million Series C financing should let the company bolster data gained already in chronic obstructive pulmonary disease (COPD), gain data in bladder pain syndrome/interstitial cystitis (BPS/IC) and then make decisions on whether to partner at the pivotal-trial stage.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription